Understanding how tumors resist treatment in lung cancer with KRAS mutations
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
This study is looking at how certain lung cancer tumors with a specific gene mutation can become resistant to treatments, and it aims to find new ways to make those treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11077754 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which tumors with KRASG12C mutations develop resistance to targeted therapies in non-small cell lung cancer (NSCLC). It focuses on the interactions between tumor cells and their surrounding environment, known as the tumor microenvironment (TME), to identify factors that contribute to treatment resistance. By analyzing these interactions, the research aims to develop new strategies to enhance the effectiveness of existing therapies and improve patient outcomes. The study will also explore the role of specific genetic alterations that may influence how tumors respond to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer harboring KRASG12C mutations.
Not a fit: Patients with non-KRAS-mutant lung cancers or those with advanced disease not amenable to targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRASG12C-mutant NSCLC, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting tumor microenvironment interactions to overcome treatment resistance in various cancers, suggesting potential for success in this area as well.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.